###### Key questions

What is already known about this subject?
=========================================

-   Copeptin has been shown to be prognostic predictor of heart failure (HF) hospitalisation and mortality in acute HF with no knowledge of whether patients have reduced (HFREF) or preserved ejection fraction (HFPEF).

What does this study add?
=========================

-   We demonstrate that in patients with HFPEF copeptin is elevated, correlates with N-terminal pro-brain natriuretic peptide but not with markers of diastolic dysfunction and is a prognostic predictor.

How might this impact on clinical practice?
===========================================

-   Knowledge on the underlying mechanisms in HFPEF is crucial for the much needed development of novel treatment options for these patients.

Introduction {#s1}
============

Patients with heart failure (HF) and a preserved ejection fraction (HFPEF) constitute nearly 50% of the HF population and HFPEF is associated with a decreased life expectancy.[@R1] Although often elderly and predominately of female gender, this is a heterogeneous group of patients with diverse comorbidities such as hypertension, atrial fibrillation, diabetes and obesity, and the definition and diagnostic tools remain controversial.[@R2] The impaired prognosis is, however, not fully explained by these conditions as higher mortality rates have been reported in patients with HFPEF than in patients with similar age and gender profile and with similar comorbidities but without the HFPEF syndrome.[@R7]

In HF several hormonal systems are suggested to be involved. One of these is the arginine vasopressin system, primarily activated by increased osmolality followed by hypovolemia, leading to vasoconstriction and water retention. In patients with HF and reduced ejection fraction (HFREF), levels of vasopressin are elevated compared to controls and correlated with disease severity.[@R8] Vasopressin is difficult to measure due to its in vitro instability and rapid clearance from the circulation. Therefore, copeptin, the stable C-terminal part of the prohormone, synthesised and released in equimolar amounts with vasopressin, is easier to measure in blood and accurately reflects vasopressin activation.[@R9]

In acute HF with no knowledge of whether left ventricular function is depressed or not copeptin has been shown to be prognostic predictor of HF hospitalisation and mortality.[@R10] In contrast, the role of the vasopressin system in patients with HFPEF is still largely unexplored. Therefore, increased understanding of its role may potentially elucidate the pathophysiological process and thus contribute to the development of new treatment strategies in HFPEF, where guideline indicated interventions are lacking.[@R13]

The present study aimed to test the hypothesis that copeptin in HFPEF is (1) elevated, (2) associated with diastolic dysfunction and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (3) predictive of HF hospitalisation and mortality.

Material and methods {#s2}
====================

This is a substudy of the The Karolinska Rennes (KaRen) which was a prospective observational multicenter study characterising patients with HFPEF. A detailed description of the protocol has been presented elsewhere.[@R14] In brief, 539 patients presenting to the hospital with acute signs and symptoms of HF according to the Framingham criteria, NT-proBNP \>300 ng/L and a left ventricular ejection fraction (LVEF) ≥45% were enrolled in French and Swedish centres. The patients returned to the hospital in stable condition 4--8 weeks after enrolment for a follow-up visit including blood sampling and echocardiography. Changes in clinical characteristics have previously been presented.[@R15] The KaRen biochemistry substudy was prespecified and included Swedish centres only. A number of 86 patients were recruited 21 May 2007 to 29 December 2011 at Karolinska University Hospital and were according to the protocol thereafter followed until 30 September 2012 when vital status was assessed by telephone contact or by the Swedish National Patient Register and Population Register. The primary outcome was according to the main study protocol defined as time to mortality from any cause or first hospitalisation due to HF. All HF hospitalisations were adjudicated and defined according to clinical judgment by the local investigator. The secondary outcome was time to mortality from any cause.

At the follow-up visit blood samples were collected in a fasting condition in the morning in ethylenediaminetetraacetic acid tubes, centrifuged and plasma was stored in aliquots in −70°C until analysis. Additionally copeptin was analysed, in the same laboratory with same method in a population-based healthy control material (n=62) matched for age within 1 year.[@R16] Copeptin was analysed with a commercial available automated immunofluorescent assay (us Kryptor Compact Plus, BRAMHS, Henningsdorf/Berlin, Germany).[@R17] [@R18] The lower detection limit of 0.9 pmol/L and interassay coefficients of variation 18.3% for 1.4 pmol/L, 6.8% for 9.3 pmol/L and less than 3% for concentrations \>18 pmol/L.[@R18]

The range of copeptin in healthy individuals has been published previously and is expressed as median (2.5th--97.5th centiles); 4.2 (1.7--11.25) pmol/L.[@R9] NT-proBNP was analysed by Elecsys electrochemiluminescence 'sandwich' immunoassay, proBNPII (Roche Diagnostics, Bromma, Sweden) with a lower detection limit of 5 ng/L and interassay coefficients of variation of ≤20%.[@R19] Creatinine was analysed by an enzymatic reaction with a modified rate Jaffe-method (Beckman Coulter, SYNCHRON system) and glomerular filtration rate (GFR) was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.[@R20]

The echocardiographic assessment was performed on a VIVID 7 echo-platform (GE VingMed, Horten, Norway) and stored in a raw-data format for off-line central analysis on Echopac PC BT12 instrumentation and software (GE Healthcare) at the Rennes University Centre for Clinical Research, France. All measurements were performed according to the recommendations of the American and European Societies of echocardiography with respect to the cardiac chamber and right heart measurements. Each examination was interpreted once and measurements were performed three times and averaged by an echocardiographist (ED) blinded to the specific clinical history of the patient.

To fulfil the definition of diastolic dysfunction two of three parameters related to diastolic function in the ESC guidelines were required. Diastolic dysfunction was defined as either left atrial volume index (LAVI; calculated as *left atrial volume* in mL divided by *body surface area* in m^2^) \>34 mL/m^2^ or left ventricular hypertrophy (LVH) assessed as left ventricular mass index (LVMI; calculated as *left ventricular mass* divided by *body surface area*) \>95 g/m^2^ in females and \>115 g/m^2^ in males in addition to either ratio of early transmitral velocity to mitral annular early velocity (E/e′) \>15 or E′\<9 cm/s, according to the European Society of Cardiology guidelines.[@R21] Additionally cardiac function was assessed as LVEF, left ventricular end diastolic diameter (LVEDd), isovolumetric relaxation time (IVRT) and E-wave deceleration time.

Continuous variables were expressed as median and quartile 1 and quartile 3 (Q1;Q3) and the Wilcoxon rank sum test was used to determine differences between groups. Categorical variables were expressed as numbers and percentages and analysed using Fisher\'s exact test. Correlations between copeptin and echocardiographic measurements of cardiac function were determined using Spearman\'s correlation coefficient. In addition correlations were assessed between copeptin and selected clinical and biochemical characteristics (age, body mass index (BMI), NT-proBNP and GFR) selected as they may influence copeptin levels and/or outcome in HFPEF.

The role of copeptin as a predictor of the primary and secondary outcomes was analysed by Cox proportional hazards model and presented as HR and 95% CI. The same variables as in the correlation analyses were used as covariates in multivariable Cox regression models (presented in [table 1](#OPENHRT2015000260TB1){ref-type="table"}). In the final multivariable model three clinically significant covariates, age, gender and NT-proBNP were included. Copeptin and NT-proBNP were log-transformed prior to analysis. All p values were two-sided and statistical significance was set at 0.05. All statistical analyses were performed using SAS software V.9.3 (SAS Institute, Cary, North Carolina, USA).

###### 

Copeptin as a predictor of all-cause mortality and/or heart failure hospitalisation in the 86 patients with HFPEF in KaRen

  Parameter                                                  All-cause mortality or HF hospitalisation (n=36)                  
  ----------------------------------------------------- ---- -------------------------------------------------- -------------- -------
  Copeptin                                               86  1.56                                               1.03 to 2.38   0.037
  Copeptin (*adjusted for age)*                          86  1.56                                               1.03 to 2.38   0.038
  Copeptin (*adjusted for gender)*                       86  1.58                                               1.04 to 2.40   0.032
  Copeptin (*adjusted for GFR)*                          85  1.69                                               0.94 to 3.01   0.078
  Copeptin (*adjusted for NT-proBNP)*                    85  1.39                                               0.91 to 2.12   0.125
  Copeptin (*adjusted for age, gender and NT-proBNP)*    85  1.40                                               0.92 to 2.14   0.119

GFR, glomerular filtration rate; HF, heart failture; HFPEF, heart failturewith preserved ejection fraction; KaRen, Karolinska Rennes Study; NT-proBNP, N-terminal pro-brain natriuretic peptide.

The KaRen study was conducted according to International Conference on Harmonisation and Good Clinical Practice guidelines and the investigation conforms with the principles outlined in the Declaration of Helsinki. The biochemistry substudy was approved by the ethical review board at Karolinska Institutet. Written and oral informed consent was obtained from all patients prior to enrolment, including a separate consent regarding the subtudy.

Results {#s3}
=======

Characteristics of all 86 patients with HFPEF divided according to presence of diastolic dysfunction are presented in [table 2](#OPENHRT2015000260TB2){ref-type="table"}. In median patients were 73 years old and 51% were females. In all patients cardiac function assessed as ejection fraction was 64% (58;68), E/e′ ratio was 10.8 (8.3;14.0) and LAVI 43 mL/m^2^ (37;53). A proportion of 23% had E/e′\>15, 67% had E′\<9, 89% had LAVI \>34 mL/m^2^ and 61% had LVH. Diastolic dysfunction was present in 52% while 35% did not fulfil the criteria. There were 5 patients with LVH and/or LAVI that did not have an E/e′\>15 or E′\<9. Eleven patients (13%) could not be classified due to missing echo variables.

###### 

Characteristics in the 86 patients in KaRen at 4--8 weeks visit

                                                   KaRen                                                              
  ------------------------------------------------ ------- -------------- ------- ------------- ------- ------------- ---------
  Patient history                                                                                                     
   Age; median (Q1;Q3)                             73      (66;79)        73      (66;80)       72      (65;72)       0.360
   Gender (male/female)                            42/44   (49/51)        19/26   (42/58)       16/14   (53/47)       0.358
   Hypertension                                    68      \(79\)         37      \(82\)        25      \(83\)        1.000
   COPD                                            14      \(16\)         8       \(18\)        5       \(17\)        1.000
   T2DM                                            27      \(31\)         17      \(38\)        8       \(27\)        0.454
   Coronary heart disease                          29      \(34\)         19      \(42\)        8       \(27\)        0.222
   Atrial fibrillation                             49      \(57\)         24      \(53\)        19      \(63\)        0.477
   NYHA class I                                    19      \(22\)         10      \(22\)        5       \(17\)        0.758
   NYHA class II                                   47      \(55\)         27      \(60\)        18      \(60\)        
   NYHA class III                                  20      \(23\)         8       \(18\)        7       \(23\)        
  Measurements                                                                                                        
   BMI (kg/m^2^)                                   29      (25;33)        29      (27;33)       27      (24;32)       0.124
   Systolic blood pressure (mm Hg)                 140     (90;210)       145     (130;150)     148     (125;155)     0.944
   Diastolic blood pressure (mm Hg)                80      (70;85)        80      (70;85)       83      (75;85)       0.152
   Heart rate (bpm)                                70      (60;80)        69      (60;78)       72      (63;84)       0.210
  Treatment                                                                                                           
   ARB                                             28      \(33\)         17      \(38\)        7       \(23\)        0.216
   ACE-inhibitor                                   42      \(49\)         21      \(47\)        16      \(53\)        0.641
   Thiazid diuretics                               14      \(16\)         7       \(16\)        5       \(17\)        1.000
   Potassium sparing diuretics                     18      \(21\)         12      \(27\)        4       \(13\)        0.250
   Loop diuretics                                  63      \(73\)         34      \(76\)        23      \(77\)        1.000
   β-blocker                                       69      \(80\)         38      \(84\)        21      \(70\)        0.159
   Anticoagulants                                  47      \(55\)         21      \(47\)        20      \(67\)        0.103
   Pacemaker                                       20      \(23\)         9       \(20\)        6       \(20\)        1.000
  ECHO parameters                                                                                                     
   LVEF (%)                                        64      (58;68)        63      (60;68)       64      (58;66)       0.847
   LAVI (mL/m^2^)                                  43.3    (37.2;52.8)    41.7    (38.2;50.8)   44.7    (37.0;55.0)   0.565
   Left atrial volume (mL)                         86.5    (75;104)       84.0    84.0          88.5    (74;106)      0.726
   Left ventricular mass index (g/m^2^)            115     (95;142)       115     (95;142)      123     (92;144)      1.000
    Male                                           125     (102;157)      143     (102;157)     121     (81;146)      0.362
    Female                                         109     (94;136)       102     (95;133)      138     (92;144)      0.379
   LVEDd (mm)                                      47      (43;53)        47      (43;53)       47      (42;54)       0.948
   E/A ratio                                       1.3     (0.9;2.5)      1.2     (0.9;2.0)     1.4     (1.1;3.4)     0.329
   E/e′ ratio                                      10.8    (8.3;14.0)     13.6    (10.0;18.2)   7.9     (7.1;9.6)     \<0.001
   E′ (cm/s)                                       8.0     (7.0;10.0)     7.5     (6.0;8.0)     10.5    (9.5:12)      \<0.001
   IVRT (diastole)                                 94      (77;113)       102     (79;119)      86      (72;102)      0.036
   Mitral VTI                                      23      (16;30)        26      (22;31)       17      (13;24)       \<0.001
   E-wave deceleration time (ms)                   203     (156;228)      205     (177;225)     164     (139;227)     0.054
  Biochemistry                                                                                                        
   Copeptin (pmol/L)                               13.56   (8.56;20.55)   11.5    (7.6;20.4)    14.7    (9.2;20.3)    0.313
    Males                                          13.93   (8.43;20.43)   13.7    (7.6;28.3)    13.6    (8.8;20.0)    0.831
    Females                                        13.06   (8.70;19.54)   10.9    (6.8;16.7)    16.0    (11.9;24.4)   0.127
   NT-proBNP (ng/L)                                1000    (469;2330)     574     (385;2330)    1320    (824;1830)    0.194
   Glomerular filtration rate (mL/min/1.73 m^2^)   68      (51;81)        68      (50;80)       77      (56;82)       0.375

Continuous variables are presented as median and lower and upper quartiles (Q1;Q3) and categorical variables as numbers (n) and percentages when not otherwise stated.

\*Eleven patients not categorised regarding diastolic dysfunction due to missing echo variables.

ARB, angiotensin receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IVRT, isovolumetric relaxation time; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; LVEDd, left ventricular end diastolic diameter; Mitral VTI, mitral to aortic velocity-time integral ratio; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; T2DM, type 2 diabetes mellitus.

In the total HFPEF cohort copeptin was 13.56 pmol/L (8.56;20.55; [table 2](#OPENHRT2015000260TB2){ref-type="table"}). The levels did not differ between patients with or without diastolic dysfunction ([figure 1](#OPENHRT2015000260F1){ref-type="fig"}). In addition copeptin was analysed in 62 healthy controls with a median age of 69 years and 44% females. Among controls 15% had hypertension, 13% type 2 diabetes and median weight was 74.5 kg. Patients with HFPEF had significantly higher levels of copeptin compared to controls, 5.98 pmol/L (4.16;9.42; p value\<0.001). There was no difference in levels of copeptin between genders among patients with HFPEF, males 13.93 (8.43;20.43) versus females 13.06 (8.70;19.54;p value=0.483), whereas in controls there was, males 7.25 (4.58;12.06) versus females 4.69 (3.21;7.11;p value=0.004).

![Copeptin levels in KaRen patients divided according to diastolic dysfunction and in healthy controls presented as boxplots displaying IQR, median (-), mean (♦) and outliers (●). Whiskers represent maximum observation within 1.5 IQR above the 75th centile.](openhrt2015000260f01){#OPENHRT2015000260F1}

Copeptin levels in patients with HFPEF did not correlate with assessed measurements of cardiac function, apart from IVRT (−0.262; p value=0.021). [Figure 2](#OPENHRT2015000260F2){ref-type="fig"} displays relations between copeptin and echochardiographic measurements included in the definition of diastolic dysfunction.

![Correlation between copeptin and biochemical markers, echocardiographic variables and clinical variables in the 86 patients in KaRen biochemistry substudy.](openhrt2015000260f02){#OPENHRT2015000260F2}

In patients with diastolic dysfunction copeptin correlated only with E/e′ (r=0.459; p value=0.003) and E′ (r=−0.402; p value=0.006) and when no diastolic dysfunction was present with LAVI (r=0.390; p value=0.033).

Both BMI and GFR correlated with copeptin in the overall HFPEF population (r=0.303; p value=0.005 and r=−0.448; p value≤0.0001) as well as with BMI in patients with diastolic dysfunction (r=0.339; p value=0.023). In patients without diastolic dysfunction there was a correlation with copeptin and GFR (r=−0.405; p value=0.026) but not with BMI. Copeptin correlated with NT-proBNP (r=0.223; p value=0.040) overall but not when the patients were divided according to diastolic function. There was no correlation between copeptin and age.

In the healthy control population copeptin correlated with age (r=0.314; p value=0.013) but not significantly with BMI (creatinine and NT-proBNP were not available).

Median follow-up time was 579 days (Q1;Q3 276;1178). No patient was lost to follow-up. The composite end point of HF hospitalisation or all-cause death occurred in 36 patients whereof 11 patients died during follow-up. In univariable analysis copeptin was a predictor of the composite end point (HR 1.56 (95% CI 1.03 to 2.38; p value=0.037)) and remained so after adjusting for age and gender ([table 1](#OPENHRT2015000260TB1){ref-type="table"}) however, not for NT-proBNP or in the multivariable model. Increasing levels of copeptin did not predict the secondary end point mortality (HR 1.85 (95% CI 0.87 to 3.94; p value=0.111)). Diastolic dysfunction was not a predictor of the composite (HR 0.93 (95% CI 0.46 to 1.88; p value=0.836) or the secondary outcome (HR 0.77 (95% CI 0.21 to 2.88; p value=0.701).

Discussion {#s4}
==========

Copeptin is elevated and predicts prognosis in HFREF but has been largely unexplored in HFPEF. Here we show that in patients with HFPEF, copeptin is elevated, correlates with NT-proBNP but not with markers of diastolic dysfunction, and is a prognostic predictor of the composite end point (HF hospitalisation or mortality) however blunted by NT-proBNP. This suggest that the HFPEF syndrome is associated with activation of copeptin however not related to measurements of an impaired diastolic function indicating that the HFPEF syndrome may be reflected more by neurohormonal activation than by diastolic dysfunction.

In the present material copeptin levels were significantly higher among patients with HFPEF (13.56 pmol/L (8.56; 20.55)) compared to a control population with similar age and gender distribution (5.98 pmol/L (4.16; 9.42)).

The elevated copeptin levels in the KaRen HFPEF cohort contrast to findings in the CIBIS-ELD trial in which copeptin levels among patients with HFPEF were in the normal range (3.7 pmol/L (2.0, 8.6)). In fact the KaRen patients had copeptin levels similar to patients with HFREF participating in the randomised controlled CIBIS-ELD trial (10.8 pmol/L (5.6; 18.2)).[@R22] This may be explained by the different inclusion criteria in the two studies with a recent acute exacerbation of HF required for inclusion criteria in KaRen and instead constituting an exclusion criterion in CIBIS-ELD[@R14] that mainly recruited chronic patients with HF. Moreover, a large proportion of KaRen patients were sicker and with more comorbidities than in the CIBIS-ELD trial. Furthermore the prevalence of diabetes, a condition associated with elevated levels of copeptin, was present in 31% of patients in KaRen and in 19% and 29% of CIBIS-ELD patients with HFPEF and HFREF, respectively.[@R23] This may indicate that the elevated copeptin levels in KaRen also, to some extent, may relate to common comorbid conditions in HFPEF such as diabetes, which indeed are also implicated in HFPEF pathophysiology.[@R24]

Also Mason *et al*[@R25] have demonstrated high levels of copeptin in HFPEF (mean 22 pmol/L (range 5--154)) comparable to patients with undifferentiated HF (mean 21 pmol/L (range 5--154))indicating increased hormonal activation. In the same report individuals without HF had a mean copeptin level of 16 pmol/L (5--184). The high copeptin levels (although reported as mean and not median which make a direct comparison difficult) may partly be explained by the study design as this was a screening study and no exclusions were made on the basis of cognitive capacity, comorbidities or immobility. Further participants defined as having no HF actually had signs of decompensation such as peripheral oedema in 40% and lung crackles in 17% of the cases.[@R26]

Activation of the vasopressin axis was one the first neurohoromonal axis described to be involved in the pathogenesis of HF.[@R27] In addition to the well-known haemodynamic effects of vasopressin, vasoconstriction and water retention, the hormone has been proposed to exert direct effects on the myocardium. These effects may be detrimental in a long-term perspective leading to left ventricular hypertrophy and remodelling in turn resulting in negative effects on myocardial contractility.[@R28] [@R29] Noteworthy in this context are findings in patients with myocardial infarction and slightly depressed LVEF where copeptin has been associated with left ventricular dysfunction and remodelling.[@R30] This is in contrast to the present results in the KaRen population with HFPEF as we did not find correlations between copeptin and measurements of cardiac function. The discrepancy may relate to differences in study design, including the measurements of cardiac function used and sample size, but more importantly differences in study population as we studied copeptin a distinct HFPEF population.

Interestingly levels of copeptin did not differ in patients with HFPEF with and without diastolic dysfunction. This may relate to the small sample size but similar baseline characteristics and comorbidities between the two groups further strengthen the speculation that elevated copeptin levels in this cohort is a marker of hormonal activation accompanied by other conditions such as renal impairment, chronic lung diseases, anaemia, cancer, liver disease common in the HFPEF population[@R5] rather than a marker of the by echocardiography defined condition diastolic dysfunction. Indeed copeptin did correlate with renal function, BMI as well as NT-proBNP but not with measurements of structural remodelling (LV hypertrophy or dilated left atrium) or raised cardiac filling pressures on echocardiography.

Of note in this context is that the patients in KaRen categorised as not having diastolic dysfunction had similar or even higher levels of copeptin and NT-proBNP however the difference not was statistically significant. This may indicate that diastolic dysfunction according to the present definition not necessarily reflect increased neurohormonal activation.

In the present HFPEF population copeptin, in unadjusted analyses, was a predictor of the composite of HF hospitalisations and mortality but not of mortality alone. Previously copeptin has been presented as a prognostic marker in HF in general[@R10] [@R30] however not, at least to the best of our knowledge, explicitly in HFPEF. The present results indicate a prognostic value of copeptin in HFPEF however blunted when adjusted for the well-established HF biomarker NT-proBNP. Thus copeptin alone may not be a biomarker to predict prognosis in HFPEF but it may add information on underlying mechanisms in this syndrome. This further supports the speculation that hormonal activation, in combination with comorbidities related to HFPEF, are of importance for prognosis and disease progression however not directly related to diastolic dysfunction, at least by the present definition.

Despite a proportionally high event rate the potential lack of power due to the small sample size is a limitation and it is therefore important to further study the potential role of copeptin as a prognostic marker in larger patient materials with HFPEF. In addition to the lack of power the sample size may have precluded the possibility to discover any differences in subgroup analyses. KaRen was designed prior to the 2012 ESC guidelines requiring structural heart disease or diastolic dysfunction on echocardiography. For inclusion, we required acute decompensated HF together with specific Framingham signs and symptoms of HF and had a range of exclusion criteria.[@R14] Nevertheless, with an NT-proBNP cut-off of 300 ng/L, we cannot exclude that some patients may not have had HF. However, median NT-proBNP levels were high and indeed higher in patients without diastolic dysfunction on echocardiography. Selection bias and measurements errors may have confounded the results.

A comparison with echocardiographic measurement\'s relation to copeptin in the control group would have been an advantage but was not available. Further serial measurements may have provided additional information on for example markers of ventricular remodelling such as temporal changes in end diastolic or systolic volumes which were associated with copeptin in the study by Kelly *et al*.[@R30] Categorising patients with atrial fibrillation as having diastolic dysfunction according to echocardiography may be difficult. As there is no established cut-off specifically for patients with atrial fibrillation they were categorised according to the same criteria as those in sinus rhythm.

Conclusion {#s5}
==========

The pathophysiology behind HFPEF, a condition associated with a poor prognosis, is still to a large extent unknown and studies on vasoactive hormones may shed some light. In the present cohort of patients with HFPEF copeptin levels were increased compared to controls and predicted the composite end point of future HF hospitalisations and mortality, however blunted by NT-proBNP. Copeptin was not correlated to measures of cardiac function including diastolic function. Our findings suggest that the HFPEF syndrome is associated with activation of vasopressin and that the pathophysiology in HFPEF is reflected by neurohormonal activation rather than by diastolic dysfunction. This is important as new information on the underlying mechanisms in HFPEF is crucial for the much needed development of novel treatment options for these patients.
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